215 related articles for article (PubMed ID: 34710325)
1. Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors.
Karim RM; Bikowitz MJ; Chan A; Zhu JY; Grassie D; Becker A; Berndt N; Gunawan S; Lawrence NJ; Schönbrunn E
J Med Chem; 2021 Nov; 64(21):15772-15786. PubMed ID: 34710325
[TBL] [Abstract][Full Text] [Related]
2. Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains.
Wang J; Erazo T; Ferguson FM; Buckley DL; Gomez N; Muñoz-Guardiola P; Diéguez-Martínez N; Deng X; Hao M; Massefski W; Fedorov O; Offei-Addo NK; Park PM; Dai L; DiBona A; Becht K; Kim ND; McKeown MR; Roberts JM; Zhang J; Sim T; Alessi DR; Bradner JE; Lizcano JM; Blacklow SC; Qi J; Xu X; Gray NS
ACS Chem Biol; 2018 Sep; 13(9):2438-2448. PubMed ID: 30102854
[TBL] [Abstract][Full Text] [Related]
3. Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites.
Olp MD; Sprague DJ; Goetz CJ; Kathman SG; Wynia-Smith SL; Shishodia S; Summers SB; Xu Z; Statsyuk AV; Smith BC
ACS Chem Biol; 2020 Apr; 15(4):1036-1049. PubMed ID: 32149490
[TBL] [Abstract][Full Text] [Related]
4. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
[TBL] [Abstract][Full Text] [Related]
5. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors.
Ember SW; Zhu JY; Olesen SH; Martin MP; Becker A; Berndt N; Georg GI; Schönbrunn E
ACS Chem Biol; 2014 May; 9(5):1160-71. PubMed ID: 24568369
[TBL] [Abstract][Full Text] [Related]
6. Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors.
Liu S; Yosief HO; Dai L; Huang H; Dhawan G; Zhang X; Muthengi AM; Roberts J; Buckley DL; Perry JA; Wu L; Bradner JE; Qi J; Zhang W
J Med Chem; 2018 Sep; 61(17):7785-7795. PubMed ID: 30125504
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
[TBL] [Abstract][Full Text] [Related]
9. Structure investigation, enrichment analysis and structure-based repurposing of FDA-approved drugs as inhibitors of BET-BRD4.
Wakchaure P; Velayutham R; Roy KK
J Biomol Struct Dyn; 2019 Aug; 37(12):3048-3057. PubMed ID: 30079805
[TBL] [Abstract][Full Text] [Related]
10. Exploiting the 7-methylimidazo[1,5-a]pyrazin-8(7H)-one scaffold for the development of novel chemical inhibitors for Bromodomain and Extraterminal Domain (BET) family.
Yang Y; Chen P; Zhao L; Zhang F; Zhang B; Xu C; Zhang H; Zhou J
Bioorg Chem; 2019 Sep; 90():103044. PubMed ID: 31220668
[TBL] [Abstract][Full Text] [Related]
11. The binding mechanism of NHWD-870 to bromodomain-containing protein 4 based on molecular dynamics simulations and free energy calculation.
Shi M; He J; Weng T; Shi N; Qi W; Guo Y; Chen T; Chen L; Xu D
Phys Chem Chem Phys; 2022 Feb; 24(8):5125-5137. PubMed ID: 35156677
[TBL] [Abstract][Full Text] [Related]
12. Structural Basis of Inhibitor Selectivity in the BRD7/9 Subfamily of Bromodomains.
Karim RM; Chan A; Zhu JY; Schönbrunn E
J Med Chem; 2020 Mar; 63(6):3227-3237. PubMed ID: 32091206
[TBL] [Abstract][Full Text] [Related]
13. Molecular docking and dynamics simulation study of flavonoids as BET bromodomain inhibitors.
Raj U; Kumar H; Varadwaj PK
J Biomol Struct Dyn; 2017 Aug; 35(11):2351-2362. PubMed ID: 27494802
[TBL] [Abstract][Full Text] [Related]
14. RVX-297- a novel BD2 selective inhibitor of BET bromodomains.
Kharenko OA; Gesner EM; Patel RG; Norek K; White A; Fontano E; Suto RK; Young PR; McLure KG; Hansen HC
Biochem Biophys Res Commun; 2016 Aug; 477(1):62-67. PubMed ID: 27282480
[TBL] [Abstract][Full Text] [Related]
15. Structural and thermodynamic characterization of the binding of isoliquiritigenin to the first bromodomain of BRD4.
Yokoyama T; Matsumoto K; Ostermann A; Schrader TE; Nabeshima Y; Mizuguchi M
FEBS J; 2019 May; 286(9):1656-1667. PubMed ID: 30565859
[TBL] [Abstract][Full Text] [Related]
16. In silico design and molecular basis for the selectivity of Olinone toward the first over the second bromodomain of BRD4.
Rodríguez Y; Gerona-Navarro G; Osman R; Zhou MM
Proteins; 2020 Mar; 88(3):414-430. PubMed ID: 31587361
[TBL] [Abstract][Full Text] [Related]
17. Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
Wellaway CR; Bamborough P; Bernard SG; Chung CW; Craggs PD; Cutler L; Demont EH; Evans JP; Gordon L; Karamshi B; Lewis AJ; Lindon MJ; Mitchell DJ; Rioja I; Soden PE; Taylor S; Watson RJ; Willis R; Woolven JM; Wyspiańska BS; Kerr WJ; Prinjha RK
J Med Chem; 2020 Sep; 63(17):9020-9044. PubMed ID: 32787145
[TBL] [Abstract][Full Text] [Related]
18. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives.
Feng L; Wang G; Chen Y; He G; Liu B; Liu J; Chiang CM; Ouyang L
Med Res Rev; 2022 Mar; 42(2):710-743. PubMed ID: 34633088
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Structure-Activity Relationships of Aristoyagonine Derivatives as Brd4 Bromodomain Inhibitors with X-ray Co-Crystal Research.
Yoo M; Park TH; Yoo M; Kim Y; Lee JY; Lee KM; Ryu SE; Lee BI; Jung KY; Park CH
Molecules; 2021 Mar; 26(6):. PubMed ID: 33802888
[TBL] [Abstract][Full Text] [Related]
20. [1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains.
Fedorov O; Lingard H; Wells C; Monteiro OP; Picaud S; Keates T; Yapp C; Philpott M; Martin SJ; Felletar I; Marsden BD; Filippakopoulos P; Müller S; Knapp S; Brennan PE
J Med Chem; 2014 Jan; 57(2):462-76. PubMed ID: 24313754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
